MedPath

ALKEM LABORATORIES LIMITED

🇮🇳India
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

51

Active:12
Completed:9

Trial Phases

4 Phases

Phase 1:9
Phase 3:17
Phase 4:17
+1 more phases

Drug Approvals

17

PHILIPPINES:16
NMPA:1

Drug Approvals

Rasagiline Mesylate Tablets

Product Name
甲磺酸雷沙吉兰片
Approval Number
国药准字HJ20240043
Approval Date
Jun 18, 2024
NMPA

Clinical Trials

Distribution across different clinical trial phases (49 trials with phase data)• Click on a phase to view related trials

Phase 3
17 (34.7%)
Phase 4
17 (34.7%)
Phase 1
9 (18.4%)
Not Applicable
6 (12.2%)
No trials found

News

Indian Pharma Companies to Launch Generic Empagliflozin at 90% Lower Cost

Several Indian pharmaceutical companies are preparing to launch generic versions of Empagliflozin following Boehringer Ingelheim's patent expiry on March 11, potentially transforming diabetes treatment accessibility.

Sonnet BioTherapeutics Advances Pipeline with Clinical Data and Strategic Partnerships

Sonnet BioTherapeutics reported stable disease in 48% of evaluable monotherapy patients in the Phase 1 SB101 trial for SON-1010 (IL12-FHAB).

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.